Carbapenemase-producing -an emerging challenge.

Carbapenem-resistant (CR-PA) is a major healthcare-associated pathogen worldwide. In the United States, 10-30% of isolates are carbapenem-resistant, while globally the percentage varies considerably. A subset of carbapenem-resistant isolates harbour carbapenemases, although due in part to limited screening for these enzymes in clinical laboratories, the actual percentage is unknown. Carbapenemase-mediated carbapenem resistance in is a significant concern as it greatly limits the choice of anti-infective strategies, although detecting carbapenemase-producing in the clinical laboratory can be challenging. Such organisms also have been associated with nosocomial spread requiring infection prevention interventions. The carbapenemases present in vary widely by region but include the Class A beta-lactamases, KPC and GES; metallo-beta-lactamases IMP, NDM, SPM, and VIM; and the Class D, OXA-48 enzymes. Rapid confirmation and differentiation among the various classes of carbapenemases is key to the initiation of early effective therapy. This may be accomplished using either molecular genotypic methods or phenotypic methods, although both have their limitations. Prompt evidence that rules out carbapenemases guides clinicians to more optimal therapeutic selections based on local phenotypic profiling of non-carbapenemase-producing, carbapenem-resistant . This article will review the testing strategies available for optimizing therapy of infections.